ANTX · AN2 Therapeutics Inc
United States · RS rating 44 · As of 2026-11-03
| Price | 4.18 USD |
|---|---|
| 1-day change | -3.9% |
| RS rating (overall / 1M / 3M / 12M) | 44 / 16 / 22 / 98 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 27 / 25 / 26 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +6.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +33.4% |
| Market cap (USD) | $154.1M |